New Adjuvant RCC Immunotherapy – Rethink RCC for T3

New Adjuvant RCC Immunotherapy – Rethink RCC for T3

We would be most grateful if you could kindly take a few minutes to answer these questions. Your valuable comments help us to improve the quality of meetings and we look forward to hearing your thoughts.

The topics discussed in this meeting are relevant to my clinical practice

Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Strongly agreeItem #1 Strongly agree	AgreeItem #1 Agree	NeutralItem #1 Neutral	DisagreeItem #1 Disagree	Strongly disagreeItem #1 Strongly disagree

The meeting increased my knowledge around novel adjuvant therapy for renal cell carcinoma

Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Strongly agreeItem #1 Strongly agree	AgreeItem #1 Agree	NeutralItem #1 Neutral	DisagreeItem #1 Disagree	Strongly disagreeItem #1 Strongly disagree

Overall, I am satisfied with this meeting

Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Strongly agreeItem #1 Strongly agree	AgreeItem #1 Agree	NeutralItem #1 Neutral	DisagreeItem #1 Disagree	Strongly disagreeItem #1 Strongly disagree

MERCK SHARP & DOHME (ASIA) LTD.
27/F Lee Garden Two, 28 Yun Ping Road, Causeway Bay, Hong Kong.
TEL: (852) 3971 2800 FAX: (852) 2834 0756
Copyright ©️ 2023 Merck & Co., Inc., Rahway, NJ, USA and its affliates. All rights reserved.
HK-KEY-00736 NOV/2023